receptor cdna
Recently Published Documents


TOTAL DOCUMENTS

288
(FIVE YEARS 1)

H-INDEX

62
(FIVE YEARS 0)

2016 ◽  
Vol 12 (3) ◽  
pp. 811-821 ◽  
Author(s):  
Priya Ravikumar ◽  
Jyothi U. Menon ◽  
Primana Punnakitikashem ◽  
Dipendra Gyawali ◽  
Osamu Togao ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Tian-You Chang ◽  
Chin-Ying Chung ◽  
Wei-Min Chuang ◽  
Long-Yuan Li ◽  
Long-Bin Jeng ◽  
...  

Background. The most common gene-based cancer therapies involve the suppression of oncogenic molecules and enhancement of the expression of tumor-suppressor genes. Studies in noncancer disease animal models have shown that minicircle (MC) DNA vectors are easy to deliver and that the proteins from said MC-carrying DNA vectors are expressed over a long period of time. However, delivery of therapeutic genes via a liposome-mediated, MC DNA complex has never been tested in vascular-rich hepatocellular carcinoma (HCC). Liposome-mediated DNA delivery exhibits highin vivotransfection efficiency and minimal systemic immune response, thereby allowing for repetitive interventions. In this study, we evaluated the efficacy of delivering an MC-liposome vector containing a 3.2 kb androgen receptor (AR; HCC metastasis suppressor) cDNA into Hepatitis B Virus- (HBV-) induced HCC mouse livers.Results. Protein expression and promoter luciferase assays revealed that liposome-encapsulated MC-AR resulted in abundant functional expression of AR protein (100 kD) for up to two weeks. The AR cDNA was also successfully delivered into normal livers and diseased livers, where it was persistently expressed. In both normal livers and livers with tumors, the expression of AR was detectable for up to 60 days.Conclusion. Our results show that an MC/liposome delivery system might improve the efficacy of gene therapy in patients with HCC.


2011 ◽  
Vol 210 (3) ◽  
pp. 369-377 ◽  
Author(s):  
Shuang-Xia Zhao ◽  
Shanli Tsui ◽  
Anthony Cheung ◽  
Raymond S Douglas ◽  
Terry J Smith ◽  
...  

The TSH receptor (TSHR) is the critical target for antibody production in Graves' disease (GD). Insulin-like growth factor 1 receptor (IGF1R) has been proposed as a second autoantigen in complications of GD such as orbitopathy. We attempted to induce orbital tissue remodeling in mice undergoing immunizations with plasmids encoding TSHR and IGF1R delivered byin vivoskeletal muscle electroporation, a procedure known to give a sustained, long-term antibody response. FemaleBALB/cmice were challenged with TSHR A-subunit or IGF1Rα subunit plasmid by injection and electroporation. Mice challenged with TSHR A-subunit plasmid resulted in high frequency (75%) of hyperthyroidism and thyroid-stimulating antibodies. But strikingly, immunization with TSHR A-subunit plasmid also elicited antibody to IGF1Rα subunit. Mice challenged in the same manner with IGF1Rα subunit plasmid produced strong antibody responses to IGF1R, but did not undergo any changes in phenotype. Simultaneous challenge by double antigen immunization with the two plasmids in distant anatomical sites reduced the incidence of hyperthyroidism, potentially as a consequence of antigenic competition. Thyroid glands from the TSHR A-subunit plasmid-challenged group were enlarged with patchy microscopic infiltrates. Histological analysis of the orbital tissues demonstrated moderate connective tissue fibrosis and deposition of Masson's trichrome staining material. Our findings imply that immunization with TSHR A-subunit plasmid leads to generation of IGF1R antibodies, which together with thyroid-stimulating antibodies may precipitate remodeling of orbital tissue, raising our understanding of its close association with GD.


2010 ◽  
Vol 168 (1) ◽  
pp. 143-148 ◽  
Author(s):  
Masaki Nakano ◽  
Itaru Hasunuma ◽  
Reiko Okada ◽  
Kazutoshi Yamamoto ◽  
Sakae Kikuyama ◽  
...  

2008 ◽  
Vol 155 (1) ◽  
pp. 255
Author(s):  
Toshie Matsumoto ◽  
Akifumi M. Nakamura ◽  
Katsuyoshi Mori ◽  
Itsuka Akiyama ◽  
Hidenori Hirose ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document